Skip to main content
. Author manuscript; available in PMC: 2023 Feb 17.
Published in final edited form as: Mol Cancer Ther. 2021 Jun 22;20(9):1692–1701. doi: 10.1158/1535-7163.MCT-21-0210

Figure 5. MSU38225 enhances the sensitivity of cancer cells to chemotherapies in vitro and in vivo.

Figure 5.

A. A549 cells were plated in a 384-well plate and co-treated with MSU38225 and chemotherapeutic agents at various concentrations for 72 hours. Cell viability was detected using CellTiter Glo assay and normalized to the DMSO control. B. A xenograft model was established using A549 cells. Tumors 4 mm in diameter were treated with either vehicle, carboplatin (5 mg/kg), MSU38225 (50 mg/kg, BID) or the combination for 4 weeks. Tumors were measured twice a week using a caliper. N=6 mice/group. **, p<0.01 vs. vehicle control. C. Body weight was measured twice a week during the treatment. Cell proliferation (D, PCNA) and Nrf2 expression (E) in tumors was evaluated by immunohistochemistry. 400x magnification. Scale bar = 60 microns.